Nkarta Inc (NKTX) Stock Price, Quote & News

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for...

Industry: Biotechnology

Sector: Healthcare

Phone: 925 407 1049

Website: www.nkartatx.com

Address:

1150 Veterans Boulevard, South San Francisco, United States

Lamatozore Aug. 6 at 7:29 AM

$NKTX soon boys

0 · Reply

purplesniper Aug. 5 at 6:32 PM

$NKTX

0 · Reply

Highbred Aug. 1 at 7:55 PM

$NKTX

0 · Reply

viking1111 Aug. 1 at 3:35 PM

$NKTX Still have 3k shares from months ago. This just doesn't have it yet.....

0 · Reply

Paulfrench Jul. 30 at 4:58 PM

$NKTX This was the first attempt to cross the 200MA, the sell orders have triggered the serious things start now😳

0 · Reply

purplesniper Jul. 30 at 4:37 PM

$NKTX let’s ride

0 · Reply

youbi336 Jul. 30 at 4:24 PM

$NKTX

0 · Reply

nightstocker15 Jul. 30 at 3:28 PM

$NKTX this has been stair stepping higher for the last month or so! Only a matter of time before it really blasts off! Take advantage here!💪🙌🐂💰

0 · Reply

Paulfrench Jul. 30 at 2:33 PM

$NKTX Hey, casually, a very beautiful bullish signal has just appeared on the graphic 1 hour !! It will soon move!

1 · Reply

purplesniper Jul. 28 at 5:00 PM

$NKTX what the heck just happened

0 · Reply

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Jul 22, 2025, 12:40 AM EDT - 16 days ago

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Jun 6, 2025, 8:52 AM EDT - 2 months ago

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

May 15, 2025, 3:46 PM EDT - 2 months ago

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 14, 2025, 4:01 PM EDT - 3 months ago

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Apr 1, 2025, 8:01 AM EDT - 4 months ago

Nkarta to Participate in an April Investor Conference

Mar 31, 2025, 10:41 AM EDT - 4 months ago

Nkarta: Grinding Lower, Trying To Find Support

Mar 31, 2025, 10:15 AM EDT - 4 months ago

Nkarta: Betting On The Turnaround

Mar 27, 2025, 12:50 PM EDT - 4 months ago

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Mar 26, 2025, 4:01 PM EDT - 4 months ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Feb 25, 2025, 8:01 AM EST - 5 months ago

Nkarta to Participate in March Investor Conferences

Dec 5, 2024, 6:01 AM EST - 8 months ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nov 26, 2024, 7:02 AM EST - 9 months ago

Nkarta to Participate in an Upcoming Investor Conference

Nov 7, 2024, 4:02 PM EST - 9 months ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 8, 2024, 9:07 AM EDT - 10 months ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

AMN MRNA

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conference

Aug 14, 2024, 3:08 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Aug 13, 2024, 9:03 PM EDT - 1 year ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Jul 24, 2024, 6:00 AM EDT - 1 year ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 16, 2024, 6:01 AM EDT - 1 year ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jun 27, 2024, 6:00 AM EDT - 1 year ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

May 25, 2024, 2:20 AM EDT - 1 year ago

Nkarta: Finally An Attractive Valuation

May 9, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Apr 27, 2024, 10:27 AM EDT - 1 year ago

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 8, 2024, 12:55 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 5, 2024, 3:35 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 3, 2024, 4:02 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conferences

Mar 25, 2024, 4:03 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25, 2024, 6:30 AM EDT - 1 year ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 13, 2024, 1:22 PM EDT - 1 year ago

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Jan 25, 2024, 12:12 PM EST - 1 year ago

Nkarta: Possible Upside From H1 Update, If Positive

Dec 9, 2023, 8:31 PM EST - 1 year ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nov 9, 2023, 4:02 PM EST - 1 year ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 7, 2023, 8:02 AM EST - 1 year ago

Nkarta to Participate at Upcoming Investor Conferences

Oct 17, 2023, 11:47 AM EDT - 1 year ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 7:01 AM EDT - 1 year ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 16, 2023, 4:01 PM EDT - 1 year ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Aug 10, 2023, 7:01 AM EDT - 2 years ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 3, 2023, 8:02 AM EDT - 2 years ago

Nkarta to Participate at Upcoming Investor Conference

Jul 5, 2023, 4:02 PM EDT - 2 years ago

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

$Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia$

Jun 27, 2023, 7:01 AM EDT - 2 years ago

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jun 26, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

Jun 10, 2023, 10:47 AM EDT - 2 years ago

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

May 11, 2023, 4:02 PM EDT - 2 years ago

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

May 11, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

TNYA

Lamatozore Aug. 6 at 7:29 AM

$NKTX soon boys

0 · Reply

purplesniper Aug. 5 at 6:32 PM

$NKTX

0 · Reply

Highbred Aug. 1 at 7:55 PM

$NKTX

0 · Reply

viking1111 Aug. 1 at 3:35 PM

$NKTX Still have 3k shares from months ago. This just doesn't have it yet.....

0 · Reply

Paulfrench Jul. 30 at 4:58 PM

$NKTX This was the first attempt to cross the 200MA, the sell orders have triggered the serious things start now😳

0 · Reply

purplesniper Jul. 30 at 4:37 PM

$NKTX let’s ride

0 · Reply

youbi336 Jul. 30 at 4:24 PM

$NKTX

0 · Reply

nightstocker15 Jul. 30 at 3:28 PM

$NKTX this has been stair stepping higher for the last month or so! Only a matter of time before it really blasts off! Take advantage here!💪🙌🐂💰

0 · Reply

Paulfrench Jul. 30 at 2:33 PM

$NKTX Hey, casually, a very beautiful bullish signal has just appeared on the graphic 1 hour !! It will soon move!

1 · Reply

purplesniper Jul. 28 at 5:00 PM

$NKTX what the heck just happened

0 · Reply

NYBomba Jul. 28 at 2:23 PM

$NKTX - with RSI in 60s and nearing 70 plus MACD above the line, it can push the DMA lines into a golden cross within 2 to 4 weeks. Lupus treatment is a solid pipeline, and with 75% institutional holdings, we can see a major breakthrough when the Golden Cross occurs....

0 · Reply

Joesh82 Jul. 25 at 12:14 PM

$NKTX Nkarta to Participate in the H.C. Wainwright “HCW@ Home” Series H.C Wainwright “HCW@ Home with Nkarta, Inc.” July 30, 2025 11:00 a.m. ET – fireside chat

0 · Reply

Paulfrench Jul. 25 at 6:23 AM

$NKTX The approach of the 200MA causes some selling, however there are no bearish signals, today will be interesting to see how the price behaves and if the buyers have enough strength to start rising again to touch the 200MA. I would be surprised if we manage to cross it on the first try (it is almost impossible) but if we do not have a reversal signal that would already be a victory...

1 · Reply

vu_jade Jul. 23 at 5:11 PM

$NKTX great look ..

0 · Reply

purplesniper Jul. 23 at 3:43 PM

0 · Reply

purplesniper Jul. 23 at 2:33 PM

$NKTX sitting on 1,010 shares

0 · Reply

Grouphome Jul. 23 at 12:21 PM

$NKTX

0 · Reply

Lukey63 Jul. 23 at 12:13 PM

$NKTX Kohls, Krispy Kreme, and even dreck like GoPro being driven up by memers. Makes me wonder what would happen with this if the memers ever catch on 😆

0 · Reply

Rafael_ Jul. 22 at 5:21 PM

$NKTX No news fake pump

0 · Reply

vu_jade Jul. 22 at 5:03 PM

$NKTX another yolo name

0 · Reply

Paulfrench Jul. 18 at 8:12 AM

Hello $NKTX I have identified a resistance zone between 2.01 and 2.16 which should be our next target to break through...

2 · Reply

Lamatozore Jul. 17 at 6:04 PM

$NKTX lets go boys!! Soon guys soon

0 · Reply

Market Cap	146.88M
Revenue (ttm)	0.00
Net Income (ttm)	-108.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	390,800
Avg Vol	500,794
Day's Range	N/A - N/A
Shares Out	70.96M
Stochastic %K	19%
Beta	0.72
Analysts	Strong Sell
Price Target	$12.80